EZH2, HIF-1, and Their Inhibitors: An Overview on Pediatric Cancers

During the past decades, several discoveries have established the role of epigenetic modifications and cellular microenvironment in tumor growth and progression. One of the main representatives concerning epigenetic modification is the polycomb group (PcG). It is composed of different highly conserved epigenetic effector proteins preserving, through several post-translational modifications of histones, the silenced state of the genes implicated in a wide range of central biological events such as development, stem cell formation, and tumor progression. Proteins of the PcG can be divided in polycomb repressive complexes (PRCs): PRC1 and PRC2. In particular, enhancer of zeste homolog 2 (EZH2), the catalytic core subunit of PRC2, acts as an epigenetic silencer of many tumor suppressor genes through the trimethylation of lysine 27 on histone H3, an essential binding site for DNA methyl transferases and histone deacetylases. A growing number of data suggests that overexpression of EZH2 associates with progression and poor outcome in a large number of cancer cases. Hypoxia inducible factor (HIF) is an important transcription factor involved in modulating cellular response to the microenvironment by promoting and regulating tumor development such as angiogenesis, inflammation, metabolic reprogramming, invasion, and metastatic fate. The HIF complex is represented by different subunits (α and β) acting together and promoting the expression of vascular endothelial growth factor (VEGF), hexokinase II (HKII), receptor for advanced glycation end products (RAGE), carbonic anhydrase (CA), etc., after binding to the hypoxia-response element (HRE) binding site on the DNA. In this review, we will try to connect these two players by detailing the following: (i) the activity and influence of these two important regulators of cancer progression in particular for what concerns pediatric tumors, (ii) the possible correlation between them, and (iii) the feasibility and efficiency to contrast them using several inhibitors.

[1]  Xu Li,et al.  The SLC34A2-ROS-HIF-1-induced up-regulation of EZH2 expression promotes proliferation and chemo-resistance to apoptosis in colorectal cancer , 2019, Bioscience reports.

[2]  M. Lind,et al.  Evolutionary consequences of epigenetic inheritance , 2018, Heredity.

[3]  R. Soffietti,et al.  STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis , 2018, Nature Medicine.

[4]  A. Shilatifard,et al.  Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma. , 2017, Cell reports.

[5]  Maolin Yan,et al.  Hypoxia induces TWIST-activated epithelial-mesenchymal transition and proliferation of pancreatic cancer cells in vitro and in nude mice. , 2016, Cancer letters.

[6]  Zhiming Wang,et al.  Hypoxia-induced NIPP1 activation enhances metastatic potential and predicts poor prognosis in hepatocellular carcinoma , 2016, Tumor Biology.

[7]  Qiang Yu,et al.  HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer , 2016, Proceedings of the National Academy of Sciences.

[8]  Q. Pang,et al.  EZH2 promotes metabolic reprogramming in glioblastomas through epigenetic repression of EAF2-HIF1α signaling , 2016, Oncotarget.

[9]  M. Israel,et al.  Pediatric Brain Tumors: Current Knowledge and Therapeutic Opportunities , 2016, Journal of pediatric hematology/oncology.

[10]  S. Armstrong,et al.  Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia , 2016, Cell reports.

[11]  C. Roberts,et al.  Targeting EZH2 in cancer , 2016, Nature Medicine.

[12]  Y. Furukawa,et al.  Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma. , 2015, The Journal of clinical investigation.

[13]  M. Caraglia,et al.  EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approaches , 2015, Journal of experimental & clinical cancer research : CR.

[14]  P. Sorensen,et al.  Translational Activation of HIF1α by YB-1 Promotes Sarcoma Metastasis. , 2015, Cancer cell.

[15]  Chris Jones,et al.  Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma , 2014, Nature Reviews Cancer.

[16]  Loredana G. Marcu,et al.  Hypoxia in Head and Neck Cancer in Theory and Practice: A PET-Based Imaging Approach , 2014, Comput. Math. Methods Medicine.

[17]  M. Hung,et al.  Regulation and Role of EZH2 in Cancer , 2014, Cancer research and treatment : official journal of Korean Cancer Association.

[18]  P. Lollini,et al.  Metformin as an Adjuvant Drug against Pediatric Sarcomas: Hypoxia Limits Therapeutic Effects of the Drug , 2013, PloS one.

[19]  Yi Jiang,et al.  EZH2: biology, disease, and structure-based drug discovery , 2013, Acta Pharmacologica Sinica.

[20]  A. Bode,et al.  Regulation of microRNAs by epigenetics and their interplay involved in cancer , 2013, Journal of experimental & clinical cancer research : CR.

[21]  A. Martelli,et al.  MYCN is a novel oncogenic target in pediatric T-cell Acute Lymphoblastic Leukemia , 2013, Oncotarget.

[22]  G. Semenza,et al.  HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. , 2013, The Journal of clinical investigation.

[23]  K. Hahn,et al.  An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. , 2013, ACS chemical biology.

[24]  Steven J. M. Jones,et al.  Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma , 2013, Acta Neuropathologica.

[25]  M. Russo,et al.  Modulators of HIF1α and NFkB in Cancer Treatment: Is it a Rational Approach for Controlling Malignant Progression? , 2012, Front. Pharmacol..

[26]  Scott L. Pomeroy,et al.  Medulloblastomics: the end of the beginning , 2012, Nature Reviews Cancer.

[27]  Tim J. Wigle,et al.  A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. , 2012, Nature chemical biology.

[28]  David T. W. Jones,et al.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.

[29]  Lei Jin,et al.  A687V EZH2 is a gain‐of‐function mutation found in lymphoma patients , 2012, FEBS letters.

[30]  J. Fangusaro.  Pediatric High Grade Glioma: a Review and Update on Tumor Clinical Characteristics and Biology , 2012, Front. Oncol..

[31]  B. Kleinschmidt-DeMasters,et al.  Clinical and molecular characteristics of congenital glioblastoma. , 2012, Neuro-oncology.

[32]  D. Haas-Kogan,et al.  High-grade gliomas in children. , 2012, Neurosurgery clinics of North America.

[33]  Elaine R. Mardis,et al.  Novel mutations target distinct subgroups of medulloblastoma , 2012, Nature.

[34]  David T. W. Jones,et al.  K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas , 2012, Acta Neuropathologica.

[35]  Stefan M. Pfister,et al.  The clinical implications of medulloblastoma subgroups , 2012, Nature Reviews Neurology.

[36]  Lynda Chin,et al.  Emerging insights into the molecular and cellular basis of glioblastoma. , 2012, Genes & development.

[37]  G. Semenza.  Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. , 2012, Trends in pharmacological sciences.

[38]  Kyeong Lee,et al.  Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. , 2012, European journal of medicinal chemistry.

[39]  Scott L. Pomeroy,et al.  Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas , 2012, Acta Neuropathologica.

[40]  Yong Jiang,et al.  Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27) , 2012, Proceedings of the National Academy of Sciences.

[41]  David T. W. Jones,et al.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.

[42]  Li Ding,et al.  Somatic Histone H3 Alterations in Paediatric Diffuse Intrinsic Pontine Gliomas and Non-Brainstem Glioblastomas , 2012, Nature Genetics.

[43]  Kiran C. Bobba,et al.  The genetic basis of early T-cell precursor acute lymphoblastic leukaemia , 2012, Nature.

[44]  M. Hung,et al.  The role of EZH2 in tumour progression , 2011, British Journal of Cancer.

[45]  Scott L. Pomeroy,et al.  Molecular subgroups of medulloblastoma: the current consensus , 2011, Acta Neuropathologica.

[46]  T. MacDonald,et al.  Treatment of high-grade glioma in children and adolescents. , 2011, Neuro-oncology.

[47]  G. Semenza.  Hypoxia-inducible factor 1: regulator of mitochondrial metabolism and mediator of ischemic preconditioning. , 2011, Biochimica et biophysica acta.

[48]  A. Chase,et al.  Aberrations of EZH2 in Cancer , 2011, Clinical Cancer Research.

[49]  Daniel J Brat,et al.  Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. , 2011, Neuro-oncology.

[50]  A. Matsumura,et al.  Hypoxia-inducible factor 1α expression is a prognostic biomarker in patients with astrocytic tumors associated with necrosis on MR image , 2011, Journal of Neuro-Oncology.

[51]  Zev A. Binder,et al.  The Genetic Landscape of the Childhood Cancer Medulloblastoma , 2011, Science.

[52]  D. Reinberg,et al.  The Polycomb complex PRC2 and its mark in life , 2011, Nature.

[53]  W. Woodward,et al.  EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. , 2011, Cancer cell.

[54]  C. Cho,et al.  Red ginseng deregulates hypoxia-induced genes by dissociating the HIF-1 dimer , 2011, Journal of Natural Medicines.

[55]  Qiang Yu,et al.  The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. , 2010, Blood.

[56]  Scott L Pomeroy,et al.  Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. , 2010, Cancer cell.

[57]  U. Dirksen,et al.  Hypoxia and hypoglycaemia in Ewing's sarcoma and osteosarcoma: regulation and phenotypic effects of Hypoxia-Inducible Factor , 2010, BMC Cancer.

[58]  H. Min,et al.  The expressions of carbonic anhydrase 9 and vascular endothelial growth factor in astrocytic tumors predict a poor prognosis. , 2010, International journal of molecular medicine.

[59]  Jianfeng Xu,et al.  Open Access Research , 2022 .

[60]  G. Semenza,et al.  Regulation of oxygen homeostasis by hypoxia-inducible factor 1. , 2009, Physiology.

[61]  D. Gillespie,et al.  Hypoxia‐regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme , 2008, Cancer.

[62]  H. Vogel,et al.  Congenital Glioblastoma Multiforme: Case Report and Review of the Literature , 2008, Pediatric Neurosurgery.

[63]  C. Verrijzer,et al.  SWI/SNF Mediates Polycomb Eviction and Epigenetic Reprogramming of the INK4b-ARF-INK4a Locus , 2008, Molecular and Cellular Biology.

[64]  G. Semenza,et al.  Hypoxia-Inducible Factor 1 (HIF-1) Pathway , 2007, Science's STKE.

[65]  G. Semenza.  Evaluation of HIF-1 inhibitors as anticancer agents. , 2007, Drug discovery today.

[66]  G. Semenza,et al.  Hypoxia-Inducible Factor 1 and Dysregulated c-Myc Cooperatively Induce Vascular Endothelial Growth Factor and Metabolic Switches Hexokinase 2 and Pyruvate Dehydrogenase Kinase 1 , 2007, Molecular and Cellular Biology.

[67]  P. Vaupel,et al.  Hypoxia in cancer: significance and impact on clinical outcome , 2007, Cancer and Metastasis Reviews.

[68]  Daniel Chourrout,et al.  Genome Regulation by Polycomb and Trithorax Proteins , 2007, Cell.

[69]  Aşkın Şeker,et al.  Congenital glioblastoma multiforme. Case report and review of the literature. , 2006, Journal of neurosurgery.

[70]  D. Nagle,et al.  Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1). , 2006, Current drug targets.

[71]  K. Aldape,et al.  Small cell astrocytoma: An aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma , 2004, Cancer.

[72]  P. Korkolopoulou,et al.  Hypoxia‐inducible factor 1α/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis , 2004, Neuropathology and applied neurobiology.

[73]  J. Olson,et al.  ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[74]  Markus Bredel,et al.  Vascular Patterns in Glioblastoma Influence Clinical Outcome and Associate with Variable Expression of Angiogenic Proteins: Evidence for Distinct Angiogenic Subtypes , 2003, Brain pathology.

[75]  L. Neckers,et al.  Hsp90 Regulates a von Hippel Lindau-independent Hypoxia-inducible Factor-1α-degradative Pathway* , 2002, The Journal of Biological Chemistry.

[76]  M. Ollerenshaw,et al.  Expression of hypoxia‐inducible factor 1α in tumours of patients with glioblastoma , 2002, Neuropathology and applied neurobiology.

[77]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[78]  G. Semenza.  Involvement of hypoxia-inducible factor 1 in human cancer. , 2002, Internal medicine.

[79]  D. Davis,et al.  Congenital glioblastoma multiforme: a report of three cases and a review of the literature , 2001, Journal of the Neurological Sciences.

[80]  G. Semenza,et al.  Expression of hypoxia‐inducible factor 1α in brain tumors , 2000 .

[81]  D. Mottet,et al.  Hypoxia‐induced activation of HIF‐1: role of HIF‐1α‐Hsp90 interaction , 1999 .

[82]  A. Singh,et al.  Picroliv - a natural product protects cells and regulates the gene expression during hypoxia/reoxygenation , 1999, Molecular and Cellular Biochemistry.

[83]  J. Caro,et al.  Hypoxia-inducible factor 1alpha (HIF-1alpha) is a non-heme iron protein. Implications for oxygen sensing. , 1998, The Journal of biological chemistry.

[84]  N. K. Kapoor,et al.  Picroliv, picroside-I and kutkoside from Picrorhiza kurrooa are scavengers of superoxide anions. , 1992, Biochemical pharmacology.

[85]  S Paget,et al.  THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .

[86]  P. Houghton,et al.  ΔNp63 promotes pediatric neuroblastoma and osteosarcoma by regulating tumor angiogenesis. , 2014, Cancer research.

[87]  P. Northcott,et al.  The epigenetics of brain tumors. , 2012, Methods in molecular biology.

[88]  S. Pfister,et al.  The clinical implications of medulloblastoma , 2012 .

[89]  D. Mottet,et al.  Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. , 1999, FEBS letters.